Dianthus Therapeutics Inc Quick Ratio (DNTH) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Dianthus Therapeutics Inc   (NASDAQ: DNTH)

Dianthus Therapeutics Inc 's Quick Ratio

DNTH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 1.95 below Dianthus Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 242 other companies have achieved higher Quick Ratio than Dianthus Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 243 to 1114.

Explain Quick Ratio?
How much Cash & cash equivalents DNTH´s has?
What are DNTH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/DNTH/financial-strength
https://api.csimarket.com/api/v1/companies/DNTH/fundamentals
https://api.csimarket.com/api/v1/companies/DNTH/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
DNTH Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 19.53 %
Y / Y Cash & cash equivalent Change -86.17 %
Quick Ratio MRQ 1.95
DNTH's Total Ranking # 1114
Seq. Current Liabilities Change -17.08 %
Seq. Cash & cash equivalent Change -48.25 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 243
Healthcare Sector # 422
Overall Market # 1114


Quick Ratio Statistics
High Average Low
42.08 15.96 3.13
(Mar 31 2024)   (Jun 30 2026)




Financial Statements
Dianthus Therapeutics Inc 's Current Liabilities $ 29 Millions Visit DNTH's Balance sheet
Dianthus Therapeutics Inc 's Cash & cash equivalent $ 56 Millions Visit DNTH's Balance sheet
Source of DNTH's Sales Visit DNTH's Sales by Geography


Cumulative Dianthus Therapeutics Inc 's Quick Ratio

DNTH's Quick Ratio for the trailling 12 Months

DNTH Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 65.74 %
Y / Y Cash & cash equivalent TTM Growth -1.15 %
Quick Ratio TTM 9.01
Total Ranking TTM # 1134
Seq. Current Liabilities TTM Growth 3.67 %
Seq. Cash & cash equivalent TTM Growth -22.65 %

Quick ratio ranking by company, industry and sector >> Back to DNTH Financial Strength Comparisons >> Go to Compare DNTH Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q3 2026 to $28.52 millions, cumulative Quick Ratio decreased to 9.01 above the DNTH average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 464 other companies have achieved higher Quick Ratio than Dianthus Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3607 to 4039.

Explain Quick Ratio?
How much Cash & cash equivalents DNTH´s has?
What are DNTH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 465
Healthcare Sector # 943
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
22.39 8.33 1.12
(Jun 30 2024)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Talphera Inc   5.29 $ 24.508  Millions$ 4.630  Millions
Rocket Pharmaceuticals Inc   5.22 $ 279.470  Millions$ 53.508  Millions
Aquestive Therapeutics Inc   5.22 $ 90.349  Millions$ 17.299  Millions
Sionna Therapeutics Inc   5.11 $ 83.878  Millions$ 16.420  Millions
Gain Therapeutics inc  4.94 $ 11.698  Millions$ 2.369  Millions
Rani Therapeutics Holdings Inc   4.91 $ 45.288  Millions$ 9.223  Millions
Abeona Therapeutics Inc   4.87 $ 134.941  Millions$ 27.707  Millions
Shattuck Labs Inc   4.84 $ 61.758  Millions$ 12.758  Millions
Mereo Biopharma Group Plc  4.75 $ 26.097  Millions$ 5.494  Millions
Spruce Biosciences Inc   4.69 $ 87.691  Millions$ 18.710  Millions
Diamedica Therapeutics Inc   4.68 $ 34.905  Millions$ 7.454  Millions
Eledon Pharmaceuticals Inc   4.61 $ 69.672  Millions$ 15.099  Millions
Septerna Inc   4.56 $ 478.601  Millions$ 104.863  Millions
Atossa Therapeutics Inc   4.37 $ 20.574  Millions$ 4.709  Millions
Adial Pharmaceuticals Inc   4.35 $ 22.000  Millions$ 5.056  Millions
Neurogene Inc   4.35 $ 78.942  Millions$ 18.163  Millions
Entrada Therapeutics Inc   4.34 $ 112.302  Millions$ 25.863  Millions
Gyre Therapeutics Inc   4.34 $ 86.190  Millions$ 19.874  Millions
Serina Therapeutics Inc   4.28 $ 19.403  Millions$ 4.529  Millions
Cellectar Biosciences Inc   4.24 $ 24.582  Millions$ 5.798  Millions
Bio Green Med Solution Inc   4.24 $ 3.454  Millions$ 0.815  Millions
Foghorn Therapeutics Inc   4.19 $ 156.222  Millions$ 37.315  Millions
Calcimedica Inc   4.12 $ 13.768  Millions$ 3.339  Millions
Revelation Biosciences Inc   3.92 $ 9.122  Millions$ 2.328  Millions
Tonix Pharmaceuticals Holding Corp   3.87 $ 162.793  Millions$ 42.026  Millions
Lyell Immunopharma Inc   3.83 $ 177.106  Millions$ 46.271  Millions
Rapport Therapeutics Inc   3.68 $ 74.754  Millions$ 20.302  Millions
Seaport Therapeutics Inc   3.60 $ 61.552  Millions$ 17.106  Millions
Xilio Therapeutics Inc   3.47 $ 122.182  Millions$ 35.258  Millions
Corbus Pharmaceuticals Holdings Inc   3.30 $ 115.337  Millions$ 34.967  Millions

Date modified: 2026-11-06T13:02:27+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.